Q3 2021 13F Holders as of 30 Sep 2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
59,112,975
-
Total 13F shares
-
33,862,280
-
Share change
-
+1,619,544
-
Total reported value
-
$762,265,836
-
Price per share
-
$22.57
-
Number of holders
-
63
-
Value change
-
+$33,803,888
-
Number of buys
-
39
-
Number of sells
-
22
Institutional Holders of Cullinan Therapeutics, Inc. - Common Stock (CGEM) as of Q3 2021
As of 30 Sep 2021,
Cullinan Therapeutics, Inc. - Common Stock (CGEM) was held by
63 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
33,862,280 shares.
The largest 10 holders included
BioImpact Capital LLC, Foresite Capital Management V, LLC, FMR LLC, VANGUARD GROUP INC, CHI Advisors LLC, BAUPOST GROUP LLC/MA, BlackRock Inc., EVENTIDE ASSET MANAGEMENT, LLC, AMERICAN INTERNATIONAL GROUP, INC., and ORBIMED ADVISORS LLC.
This page lists
63
institutional shareholders reporting positions in this security
for the Q3 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.